Researchers examined the impact that time-to-initiation of biologic treatment had on the risk of adverse outcomes among individuals with Crohn disease.
Clostridioides difficile infection can present much like an IBD flare. Getting to the right diagnosis is critical in controlling this condition, which was the topic of a session presented by Jessica...
Working with patients with inflammatory bowel disease who are or wish to become pregnant presents special challenges. Kim Isaacs, MD, shared her insights at the virtual Advances in Inflammatory Bowel...
The ACG’s treatment guidelines for Crohn disease offer significant lessons for physicians. David A. Schwartz, MD, provided an overview at the Advances in Inflammatory Bowel Disease virtual regional meeting...
Biosimilars show promise in reducing costs and equaling efficacy, compared with originator compounds. But will they live up to that potential? Russell Cohen, MD, addressed these issues and more at the...
What exactly is precision medicine, and is it ready to be applied in gastroenterology practice? Millie Long, MD, discussed the topic at the virtual Advances in Inflammatory Bowel Disease regional meeting on...
Applying a systematic treat-to-target approach is effective for reducing the risk of long-term complications in patients with IBD, but incremental benefit must be evaluated. Siddarth Singh, MD, spoke about...
In her session, Millie Long, MD, reviewed the role of anticytokine therapy for treating Crohn disease and how new approaches to diagnosing, monitoring, and treating Crohn disease have helped advance the...
The many different classes of medications available for treating inflammatory bowel disease give gastroenterologists more options than ever before—and also more challenges in determining how to balance...
